Borrelia lanei sp. nov. extends the diversity of Borrelia species in California
The diversity of Borrelia species discovered in California appears to be particularly high. A divergent group of Borrelia strains collected from Ixodes ticks in California was described by Postic and co-workers and designated ‘genomospecies 2’ (Postic D, Garnier M, Baranton G. Int J Med Microbiol2007;297:263–271; Postic D, Ras NM, Lane RS, Hendson M, Baranton G. J Clin Microbiol1998;36:3497–3504). We performed multilocus sequence analysis (MLSA) using eight housekeeping loci (clpA, clpX, nifS, pepX, pyrG, recG, rplB and uvrA) on 12 strains of this Borrelia genospecies to confirm that these strains form a distinct group within the Borrelia burgdorferi s. l. complex (Margos G, Hojgaard A, Lane RS, Cornet M, Fingerle V et al. Ticks Tick Borne Dis 2010;1:151–158). Phylogenetic and genetic distance analyses based on sequences of the MLSA housekeeping genes corroborated the distinctness of this group; genetic distances to all other members of the B. burgdorferi s.l. complex were 96 % or lower. We propose the name Borrelia lanei sp. nov. for this genospecies in honor of Professor Robert S. Lane, University of California Berkeley, for his contributions to Borrelia and tick research. The type strain for Borrelia lanei sp. nov., strain CA28-91T, has been deposited to two culture collections (=DSM 17992T=CIP 109135T).
Congrats to Dr. Lane for this borrelia strain discovery. Lane is also a member of the newly formed Tick Research to Eliminate Diseases: Scientist Coalition (TRED): https://madisonarealymesupportgroup.com/2017/04/12/announcing-tred-tick-research-to-eliminate-diseases-scientist-coalition/
This could also explain why California Lyme patients are discarded like yesterday’s trash. They very probably have these yet to be discovered strains of borrelia that no CDC two tiered test is going to pick up in a trillion years.
Much work needs to be done not only in discovering these strains but also the other pathogens involved that make our cases much more complex than the average GP understands. These factors could well explain why we aren’t testing positively and why we are not getting better with the mono therapy of doxycycline.